MSLN and breast carcinoma: Antigens that are now being targeted in breast cancer clinical research include HER2, mesothelin, CEA, CAIX, FR-α, CD171, GD2, EGFRvIII, FAP, and vascular endothelial growth factor receptor2 (VEGF-R2) [122, 123, 124].